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Abstract
Leprosy is an infectious disease caused by Mycobacterium leprae. The polymerase chain reaction (PCR) has been applied to 
detect M. leprae in different clinical samples and urine seems to be attractive for this purpose. PCR was used to improve the 
sensitivity for diagnosing leprosy by amplifying a 151-bp PCR fragment of the M. leprae pra gene (PCR-Pra) in urine samples. 
Seventy-three leprosy patients (39 males and 34 females, 14 to 78 years old) were selected for leprosy diagnosis at a refer-
ence laboratory in Maringá, PR, Brazil. Of these, 36 were under anti-leprosy multidrug therapy with dapsone and rifampicin for 
tuberculoid (TT) and dapsone, rifampicin and clofazimine for borderline (BB) and lepromatous (LL) forms. The control group 
contained 50 healthy individuals without any clinical history of leprosy. DNA isolated from leprosy patients’ urine samples was 
successfully amplified by PCR-Pra in 46.6% (34/73) of the cases. The positivity of PCR-Pra for patients with the TT form was 
75% for both patients under treatment and non-treated patients (P = 0.1306). In patients with the LL form, PCR-Pra positivity 
was 52 and 30% for patients under treatment and non-treated patients, respectively (P = 0.2386). PCR-Pra showed a statistically 
significant difference in detecting M. leprae between the TT and LL forms of leprosy in patients under treatment (P = 0.0033). 
Although the current study showed that the proposed PCR-Pra has some limitations in the detection of M. leprae, this method has 
the potential to be a useful tool for leprosy diagnosis mainly in TT leprosy where the AFB slit-skin smear is always negative.
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The polymerase chain reaction (PCR) has been ap-
plied to detect Mycobacterium leprae in different clinical 
samples, such as slit-skin smear (1), blood (2), nasal cavity 
(3,4), skin tissues (2,5), and urine (6) for the improvement 
of the laboratory diagnosis of leprosy. PCR targets are 
genes that encode protein antigens of 36 kDa, known as 
proline-rich antigen (pra) (2,6,7), of 18 kDa (8), 85 kDa (5), 
65 kDa (9), 16S rRNA (1), and repetitive sequences (10) 
to detect M. leprae.
Some studies have reported the presence of myco-
bacterial DNA in urine (6,11), a fact that makes this clinical 
specimen attractive for the detection of M. leprae DNA. This 
is due to the fact that urine samples are easily collected 
and enhance patient adherence when compared to the 
distressing and traumatic slit-skin smear.
Parkash et al. (6) detected M. leprae DNA in the urine 
of leprosy patients when they used primers proposed by 
Hartskeerl et al. (7), which amplified a large fragment of 
DNA (530 bp) of the pra encoding gene, even though the 
sample studied had a limited number of individuals. As small 
fragments of bacterial DNA may be found in patient urine 
samples (10), the use of this kind of clinical samples and 
primer set to detect a smaller fragment of M. leprae should 
be better evaluated since the amplification of a smaller DNA 
fragment may improve the sensitivity of the PCR assay, as 
pointed out by Goulart et al. (12). 
As the structure of the primers can be critical for the 
PCR assay, in the current study we evaluated a new primer-
PCR for the detection of the M. leprae pra gene (PCR-Pra) 
in urine samples.
Material and Methods
Study population
Seventy-three patients from northwestern Paraná 
State with a clinical diagnosis of leprosy were selected at 
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Laboratório de Ensino e Pesquisa em Análises Clínicas 
(LEPAC), Universidade Estadual de Maringá (UEM), PR, 
Brazil, from June 2006 to June 2007. Individuals with a clini-
cal and laboratory diagnosis by microscopy (Ziehl-Gabett) 
were included. Individuals with kidney or vascular diseases 
were excluded. Patients were classified by physicians using 
clinical signs and bacteriological criteria and assigned to 
the following leprosy forms according to Ridley and Jopling 
(13): tuberculoid (TT, N = 12), borderline-borderline (BB, N 
= 14), lepromatous (LL, N = 45), and indeterminate (II, N = 
2). Thirty-two patients were under anti-leprosy therapy with 
dapsone, rifampicin and clofazimine for multibacillary forms 
(slit-skin smear-positive BB and LL patients) and 4 were 
treated with dapsone and rifampicin for paucibacillary forms 
(slit-skin smear-negative TT and II patients). The variables 
age, gender, and family history of non-treated leprosy and 
anti-leprosy therapy were analyzed.
A control group consisted of 50 healthy individuals with-
out any clinical history of leprosy and without any cases of 
the disease in their families. 
The study was approved by the Ethics Committee of 
Universidade Estadual de Maringá (protocol No. 131/2006). 
All participants approved the research protocol and gave 
informed written consent.
DNA extraction from urine samples
Two first-emission urine samples (approximately 12 mL 
each) were collected from all participants on consecutive 
days, homogenized and placed in a boiling water bath for 10 
min and then centrifuged at 12,000 g for 20 min. DNA extrac-
tion was carried out as described by Sechi et al. (11).
PCR-Pra
The primers Pra1 (5’-ATCCGCTCACTGCCTAAGGA-3’) 
and Pra2 (5’-TGCGTGATATCAGTGACGGAC-3’) were 
designed to amplify a 151-bp segment of the M. leprae pra 
gene (GenBank accession No. X65546.1). The sequences 
were aligned using the Prime Premier® V. 5.0 software 
(Premier Biosoft International, USA). PCR-Pra assays were 
performed using 5 µL template in 20 µL of a reaction mixture 
containing 200 nM primers (Integrated DNA Technologies, 
USA) and PCR Master Mix (Promega Corporation, USA) 
according to manufacturer instructions. The amplification 
was carried out in an Eppendorf thermocycler (Mastercy-
cler® gradient PCR, Germany) using an initial cycle of 5 
min at 95°C, 35 cycles of 60 s at 95°C, 60 s at 54°C, 60 
s at 72°C, and a final extension of 10 min at 72°C. PCR 
products were separated by 2% agarose gel electrophoresis 
in Tris-borate-EDTA (TBE) buffer for 1 h at 100 V and the 
gels were stained with ethidium bromide. A 100-bp DNA 
Ladder (Invitrogen Life Technologies, Brazil) was used as 
a molecular marker. Positive and negative controls were 
included in all amplifications. Five microliters of DNA ex-
tracted (0.15 µg/mL) from an armadillo’s skin lesion was 
added to the PCR reagents for the positive controls, and 
5 µL TBE was added to the PCR reagents to serve as the 
negative controls.
Specificity and sensitivity of the PCR
The specificity of the PCR-Pra for the detection of M. 
leprae in urine was evaluated using DNA extracted from 
M. leprae obtained from a skin lesion of an armadillo ex-
perimentally infected and kindly supplied by the animal 
laboratory of Institute Lauro de Souza Lima (São Paulo, 
Brazil). Reference strains of M. tuberculosis H37Rv (ATCC 
27.294), M. bovis AN5, M. gordonae (Lacen/Pr), M. avium 
(ATCC 13.950), M. kansasii (Lacen/Pr), M. fortuitum (Lacen/
Pr), M. szulgai (Lacen/Pr), M. flavescens (Lacen/Pr), and 
M. smegmatis (Lacen/Pr) were also used. The DNA was 
extracted using a phenol-chloroform method (14). Sensitiv-
ity was determined using total DNA (M. leprae) obtained 
from a skin lesion of an armadillo (90 µg/mL) and diluted 
1:100 (0.90 µg/mL), 1:300 (0.30 µg/mL), 1:600 (0.15 µg/
mL), and 1:1200 (0.075 µg/mL). The detection of PCR 
inhibitors in urine samples was carried out by the addition 
of 5 µL DNA extracted (0.15 µg/mL) from a skin lesion of 
an armadillo to a 20-µL aliquot of each DNA extracted from 
urine samples.
Data analysis
Clinical samples were considered to be positive for 
the presence of M. leprae DNA when a single band of 
PCR product (151 bp) was observed and considered 
to be negative by the absence of amplification after the 
observation of PCR controls. In the absence of amplifica-
tion of the positive controls, samples and their respective 
controls were amplified using diluted (1:2) DNA extracted 
from urine samples.
Data were analyzed with non-parametric tests for pro-
portions, McNemar test, chi-square test, and G test, using 
BioEstat 5.0 (Federal University of Pará, Brazil), with the 
level of significance set at P < 0.05.
Results
The mean age of patients with leprosy was 46 years 
(range: 14-78) and a higher prevalence was observed in 
women (51.4%) and men (58.3%) among the non-treated 
patients and patients under treatment, respectively. A 
higher proportion of patients (41.7%) with a family history 
of leprosy was observed among patients under treatment. 
The highest positivity of PCR-Pra was observed in male 
patients aged 31 to 60 years and in patients with a family 
history of leprosy. However, no significant difference was 
observed between patients under treatment and non-treated 
patients considering gender, age, family history of leprosy, 
and positivity of PCR-Pra (P > 0.005; Table 1).
PCR-Pra was specific for the detection of M. leprae 
and detected DNA up to 1:600 (0.15 µg/mL) dilution. No 
amplification was observed in DNA from M. tuberculosis, M. 
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gordonae, M. avium, M. kansasii, M. fortuitum, M. szulgai, 
M. flavescens, M. smegmatis, and M. bovis.
DNA isolated from urine samples was also successfully 
amplified by PCR-Pra, which was positive in 46.6% (34/73) 
of all patients studied. No significant difference in PCR 
positivity was observed between patients under treatment 
and non-treated patients with the TT (P = 0.1306) and LL 
(P = 0.2386) forms. The positivity of PCR-Pra was higher 
in patients under treatment with the TT form (75%) than in 
patients with the LL form (52%) (P = 0.0033). No significant 
difference in M. leprae detection was observed between 
patients with the TT and LL forms in the diagnostic phase of 
leprosy (P = 0.2889) (Table 2). Initial PCR-Pra inhibition in 
non-treated leprosy patients was observed in 24.3% (9/37) 
of the total samples studied. The diluted DNA 
extracts (1:2) showed PCR inhibitors in 13.5% 
(5/37) of samples.
No amplification was observed in the healthy 
control group (Table 2).
Discussion
An epidemiological study (15) indicated that 
adult males and people with a family history of 
leprosy are more vulnerable to leprosy. In the cur-
rent study, the PCR-Pra positivity was consistent 
with the literature, with a higher positivity among 
males aged 31 to 60 years with a family history 
of leprosy.
Variation in M. leprae PCR positivity has been 
mainly related to different primers used (5), ampli-
fied fragment size (12), amplification techniques 
(16), and clinical specimens (2,6). The PCR-Pra 
intended to detect M. leprae in urine samples 
by amplifying a 151-bp DNA fragment of the pra 
gene, which was smaller than that described by 
Hartskeerl et al. (7) and other proposed PCR for 
improving PCR assay sensitivity.
PCR-Pra showed specific detection of M. 
leprae among the other mycobacteria tested and showed 
overall higher sensitivity (46.6%) in detecting M. leprae 
in urine than that obtained by Parkash et al. (6) targeting 
the pra gene (37.5%) and Caleffi et al. (17) targeting 85 
A-C intergenic region (4.10%) in previous studies, which 
amplified a 530- and a 250-bp DNA fragment, respectively. 
This result suggests that the amplification of a smaller DNA 
fragment (151 bp) by PCR-Pra may improve the perfor-
mance of PCR-based methods for detecting M. leprae in 
urine samples, as pointed out by Goulart et al. (12). It is 
important to emphasize that small fragments of bacterial 
DNA may be found in urine samples as a result of DNA 
damage by antimicrobial therapy and/or by its processing 
and excretion (10,18).
Table 1. Distribution of non-treated leprosy patients and leprosy patients 
under treatment regarding gender, age, family history of leprosy, and PCR-
Pra results.
No. of non-treated 
patients (%) 
No. of patients 
under treatment (%) 
Positive 
PCR-Pra (%)
Gender
Female 19 (51.4) 15 (41.7) 15 (44.1)
Male 18 (48.6) 21 (58.3) 19 (48.7)
Age (years)
 5-17 1 (2.7) 0 (0.0) 0 (0.0)
18-30 2 (5.4) 7 (19.4) 3 (33.3)
31-45 10 (27.0) 8 (22.2) 9 (50.0)
46-60 18 (48.6) 17 (47.2) 19 (54.3)
61-78 6 (16.2) 4 (11.1) 3 (30.0)
Total 37 (100) 14 (37.8)
Total 36 (100) 20 (55.5)
Family history of leprosy
Yes 7 (18.9) 15 (41.7) 14 (63.6)
No 30 (81.1) 21 (58.3) 20 (39.2)
PCR-Pra = positivity vs gender, family history of leprosy (P > 0.05; chi-
square test). PCR-Pra positivity vs age (P > 0.05; G test).
Table 2. Performance of PCR-Pra for the detection of Mycobacterium leprae in urine according to the clinical form of non-treated 
patients and patients under treatment.
PCR positivity (%)
Non-treated patients Patients under treatment Total Control group
II TT BB LL Total II TT BB LL Total Total
PCR-Pra (0/2) 75.0 
(6/8)
28.6 
(2/7)
30.0 
(6/20)
37.8 
(14/37)
(0/0) 75.0 
(3/4)
57.1 
(4/7)
52.0
(13/25)
55.5 
(20/36)
46.6
(34/73)
(0/50)
The number of individuals is given in parentheses. II = indeterminate leprosy; TT = tuberculoid leprosy; BB = borderline leprosy; 
LL = lepromatous leprosy. P = 0.1306 (McNemar test), PCR results vs patients with the TT form. P = 0.2386 (McNemar test), PCR 
results vs patients with the LL form. P = 0.2889 (McNemar test), PCR results vs non-treated patients with the TT form and the LL 
form. P = 0.0033 (McNemar test), PCR results vs patients with the TT and LL forms under treatment.
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Parkash et al. (6) observed high PCR positivity in 
patients under anti-leprosy treatment (66.7%) compared 
to non-treated patients (20.0%). In the present study, in 
which PCR-Pra was applied to a larger number of patients, 
the difference between these groups of patients was not 
statistically significant.
In the case of patients under treatment, PCR-Pra 
showed a significant difference between the TT and LL 
forms of leprosy (P = 0.0033). This result may be asso-
ciated with the action of the antimicrobial, cell immune 
response, increased excretion of dead bacilli by the kid-
neys in the TT form of leprosy, and a higher sensitivity of 
the PCR-Pra by amplification of a smaller DNA fragment 
(12). Since the cell immune response, predominant in the 
TT form, is more efficient in combating the bacilli than the 
humoral immune response, predominant in the LL form, the 
excretion of a greater amount of free DNA by the kidneys 
would be expected to occur in the TT form as reported by 
Parkash et al. (6) and in the previous study targeting the 
85 A-C intergenic region using the same clinical samples 
from non-treated patients (diagnostic phase) (16). How-
ever, PCR-Pra positivity showed no statistically significant 
difference among patients with the TT and LL forms in the 
diagnostic phase (P = 0.2889).
PCR-Pra proved to be highly useful to confirm the diag-
nosis of leprosy, especially in the TT form (75% PCR-Pra 
positivity in patients under treatment and in non-treated 
patients), where microscopic detection of AFB in slit-skin 
smears is normally negative owing to the low number of 
bacilli present in clinical samples (19).
In the current study, certain interfering elements were 
present in the urine samples, which resulted in PCR inhibi-
tion. Urine normally contains substances such as insoluble 
amorphous salts, nitrate, urea, proteins, blood, and even 
high ratios of human genomic DNA, which can inhibit 
PCR (5). Thus, the effect of PCR inhibitors in urine may 
have been reduced when the DNA samples were diluted. 
A significant reduction (10.8%) in PCR inhibition rate was 
consequently observed in patients in the diagnostic phase. 
Since the dilution of M. leprae DNA probably occurred 
simultaneously, detection of the bacillus turned out to be 
difficult in some cases. 
It is noteworthy that the nucleic acids in urine or other 
clinical specimens detected by PCR do not necessarily indi-
cate the presence of viable M. leprae in the human organism 
(20). PCR results are slow to turn negative after the start of 
antimicrobial therapy. This is due to the presence of DNA 
fragments, which remain in circulation for several weeks 
after death of the bacilli (11). The time period during which 
M. leprae DNA may be excreted in urine is unknown since 
the bacilli have already been reported to last up to 8 years 
after the completion of anti-leprosy therapy (3).
PCR-Pra showed some potential as a useful assay 
for the detection of M. leprae DNA in urine samples, with 
a further asset for the diagnosis of leprosy mainly in the 
TT form or in inconclusive cases where the AFB slit-skin 
smear is always negative. PCR-Pra should be evaluated 
in an extended number of patients from endemic and non-
endemic regions to address limitations such as performing 
a multiplex-PCR in urine with an internal control.
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